Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 5OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 134Urinary Bladder Neoplasms 47Kidney Neoplasms 38Carcinoma, Renal Cell 30Wilms Tumor 29Testicular Neoplasms 21Urethral Neoplasms 16Ovarian Neoplasms 15Neoplasm Metastasis 14Breast Neoplasms 14Neuroblastoma 12Sarcoma 11Teratoma 10Carcinoma, Non-Small-Cell Lung 9Testicular Germ Cell Tumor 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Ovarian Germ Cell Cancer 8Lung Neoplasms 8Endodermal Sinus Tumor 8Colorectal Neoplasms 7Burkitt Lymphoma 7Seminoma 6Osteosarcoma 6Neoplasms 6Colonic Neoplasms 6Carcinoma, Ovarian Epithelial 6Teratoma, Testicular 5Recurrence 5Pain 5Head and Neck Neoplasms 5

Interventions

Docetaxel 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Metastatic Hormone-sensitive Prostate Cancer × Genitourinary × Clear all
NCT00309985 2025-12-11

CHAARTED

Eastern Cooperative Oncology Group

Phase 3 Completed
790 enrolled 11 charts
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡